These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38009954)

  • 1. COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial.
    Habtehyimer F; Zhu X; Redd AD; Gebo KA; Abraham AG; Patel EU; Laeyendecker O; Gniadek TJ; Fernandez RE; Baker OR; Ram M; Cachay ER; Currier JS; Fukuta Y; Gerber JM; Heath SL; Meisenberg B; Huaman MA; Levine AC; Shenoy A; Anjan S; Blair JE; Cruser D; Forthal DN; Hammitt LL; Kassaye S; Mosnaim GS; Patel B; Paxton JH; Raval JS; Sutcliffe CG; Abinante M; Oei KS; Cluzet V; Cordisco ME; Greenblatt B; Rausch W; Shade D; Gawad AL; Klein SL; Pekosz A; Shoham S; Casadevall A; Bloch EM; Hanley D; Tobian AAR; Sullivan DJ
    Microbiol Spectr; 2024 Jan; 12(1):e0328623. PubMed ID: 38009954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname.
    Bihariesingh-Sanchit R; Bansie R; Ramdhani N; Mangroo R; Bustamente D; Diaz E; Fung A Foek C; Thakoer I; Vreden S; Choudhry Z; van 't Wout AB; Diavatopoulos DA; Nierich AP
    mBio; 2023 Apr; 14(2):e0337922. PubMed ID: 36815780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
    De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
    Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial.
    Bégin P; Callum J; Heddle NM; Cook R; Zeller MP; Tinmouth A; Fergusson DA; Cushing MM; Glesby MJ; Chassé M; Devine DV; Robitalle N; Bazin R; Shehata N; Finzi A; McGeer A; Scales DC; Schwartz L; Turgeon AF; Zarychanski R; Daneman N; Carl R; Amorim L; Gabe C; Ellis M; Sachais BS; Loftsgard KC; Jamula E; Carruthers J; Duncan J; Lucier K; Li N; Liu Y; Armali C; Kron A; Modi D; Auclair MC; Cerro S; Avram M; Arnold DM
    Trials; 2021 May; 22(1):323. PubMed ID: 33947446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial.
    Shoham S; Bloch EM; Casadevall A; Hanley D; Lau B; Gebo K; Cachay E; Kassaye SG; Paxton JH; Gerber J; Levine AC; Naeim A; Currier J; Patel B; Allen ES; Anjan S; Appel L; Baksh S; Blair PW; Bowen A; Broderick P; Caputo CA; Cluzet V; Cordisco ME; Cruser D; Ehrhardt S; Forthal D; Fukuta Y; Gawad AL; Gniadek T; Hammel J; Huaman MA; Jabs DA; Jedlicka A; Karlen N; Klein S; Laeyendecker O; Lane K; McBee N; Meisenberg B; Merlo C; Mosnaim G; Park HS; Pekosz A; Petrini J; Rausch W; Shade DM; Shapiro JR; Singleton JR; Sutcliffe C; Thomas DL; Yarava A; Zand M; Zenilman JM; Tobian AAR; Sullivan DJ
    Clin Infect Dis; 2023 Feb; 76(3):e477-e486. PubMed ID: 35579509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds.
    Larkey NE; Ewaisha R; Lasho MA; Roforth MM; Granger D; Jerde CR; Wu L; Gorsh A; Klassen SA; Senefeld JW; Joyner MJ; Baumann NA; Theel ES; Mills JR
    Microbiol Spectr; 2022 Aug; 10(4):e0115422. PubMed ID: 35862939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of SARS-CoV-2-independent immunoregulatory activity of COVID-19 convalescent plasma.
    Brox R; Achenbach S; Hackstein H
    Transfusion; 2021 Nov; 61(11):3087-3093. PubMed ID: 34546583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.
    Bar KJ; Shaw PA; Choi GH; Aqui N; Fesnak A; Yang JB; Soto-Calderon H; Grajales L; Starr J; Andronov M; Mastellone M; Amonu C; Feret G; DeMarshall M; Buchanan M; Caturla M; Gordon J; Wanicur A; Monroy MA; Mampe F; Lindemuth E; Gouma S; Mullin AM; Barilla H; Pronina A; Irwin L; Thomas R; Eichinger RA; Demuth F; Luning Prak ET; Pascual JL; Short WR; Elovitz MA; Baron J; Meyer NJ; Degnan KO; Frank I; Hensley SE; Siegel DL; Tebas P
    J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34788233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation.
    Van Rompay KKA; Olstad KJ; Sammak RL; Dutra J; Watanabe JK; Usachenko JL; Immareddy R; Roh JW; Verma A; Shaan Lakshmanappa Y; Schmidt BA; Di Germanio C; Rizvi N; Liu H; Ma ZM; Stone M; Simmons G; Dumont LJ; Allen AM; Lockwood S; Pollard RE; Ramiro de Assis R; Yee JL; Nham PB; Ardeshir A; Deere JD; Jain A; Felgner PL; Coffey LL; Iyer SS; Hartigan-O'Connor DJ; Busch MP; Reader JR
    PLoS Pathog; 2022 Apr; 18(4):e1009925. PubMed ID: 35443018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma.
    Estcourt LJ; Cohn CS; Pagano MB; Iannizzi C; Kreuzberger N; Skoetz N; Allen ES; Bloch EM; Beaudoin G; Casadevall A; Devine DV; Foroutan F; Gniadek TJ; Goel R; Gorlin J; Grossman BJ; Joyner MJ; Metcalf RA; Raval JS; Rice TW; Shaz BH; Vassallo RR; Winters JL; Tobian AAR
    Ann Intern Med; 2022 Sep; 175(9):1310-1321. PubMed ID: 35969859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dose Convalescent Plasma for Treatment of Severe COVID-19.
    De Santis GC; Oliveira LC; Garibaldi PMM; Almado CEL; Croda J; Arcanjo GGA; Oliveira ÉAF; Tonacio AC; Langhi DM; Bordin JO; Gilio RN; Palma LC; Santos EV; Haddad SK; Prado BPA; Pontelli MC; Gomes R; Miranda CH; Auxiliadora Martins M; Covas DT; Arruda E; Fonseca BAL; Calado RT
    Emerg Infect Dis; 2022 Mar; 28(3):548-555. PubMed ID: 35081022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 convalescent plasma.
    Tobian AAR; Cohn CS; Shaz BH
    Blood; 2022 Jul; 140(3):196-207. PubMed ID: 34695186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID 19 convalescent plasma: Is there still a place for CCP?
    Moog R
    Transfus Apher Sci; 2023 Apr; 62(2):103680. PubMed ID: 36870907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study.
    Alsharidah S; Ayed M; Ameen RM; Alhuraish F; Rouheldeen NA; Alshammari FR; Embaireeg A; Almelahi M; Adel M; Dawoud ME; Aljasmi MA; Alshammari N; Alsaeedi A; Al-Adsani W; Arian H; Awad H; Alenezi HA; Alzafiri A; Gouda EF; Almehanna M; Alqahtani S; Alshammari A; Askar MZ
    Int J Infect Dis; 2021 Feb; 103():439-446. PubMed ID: 33285283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of COVID-19 Patients with Two Units of Convalescent Plasma in a Resource-Constrained State.
    Ipe TS; Ugwumba B; Spencer HJ; Le T; Ridenour T; Armitage J; Ryan S; Pearson S; Kothari A; Patil N; Dare R; Crescencio JCR; Venkata A; Laudadio J; Mohammad K; Jamal N; Thompson J; McNew H; Gibbs M; Hennigan S; Kellar S; Reitzel K; Walser BE; Novak A; Quinn B
    Lab Med; 2022 Nov; 53(6):623-628. PubMed ID: 35771890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy.
    Herman JD; Wang C; Burke JS; Zur Y; Compere H; Kang J; Macvicar R; Taylor S; Shin S; Frank I; Siegel D; Tebas P; Choi GH; Shaw PA; Yoon H; Pirofski LA; Julg BD; Bar KJ; Lauffenburger D; Alter G
    Cell Rep Med; 2022 Nov; 3(11):100811. PubMed ID: 36351430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment.
    Karaba AH; Johnston TS; Beck E; Laeyendecker O; Cox AL; Klein SL; Sullivan DJ;
    mBio; 2023 Feb; 14(1):e0328722. PubMed ID: 36625657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood Endothelial-Cell Extracellular Vesicles as Potential Biomarkers for the Selection of Plasma in COVID-19 Convalescent Plasma Therapy.
    Amri N; Tessier N; Bégin R; Vachon L; Bégin P; Bazin R; Loubaki L; Martel C
    Cells; 2022 Oct; 11(19):. PubMed ID: 36231083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.
    Delgado-Fernández M; García-Gemar GM; Fuentes-López A; Muñoz-Pérez MI; Oyonarte-Gómez S; Ruíz-García I; Martín-Carmona J; Sanz-Cánovas J; Castaño-Carracedo MÁ; Reguera-Iglesias JM; Ruíz-Mesa JD
    Enferm Infecc Microbiol Clin (Engl Ed); 2022 Nov; 40(9):507-516. PubMed ID: 36336380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.